Alector (ALEC) Income from Continuing Operations (2018 - 2026)
Alector's (ALEC) quarterly Income from Continuing Operations came in at 22930000.0 in Q1 2026, up 43.34% year-on-year from 15996690.86 in Q1 2025, and up 38.19% on a QoQ basis from 37099000.0 in Q4 2025.
Alector (ALEC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Income from Continuing Operations data on file, last reported at 22930000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 43.34% year-over-year to 22930000.0 in Q1 2026; TTM through Mar 2026 was 125220000.0, a 1.44% decrease from a year earlier, with the FY2025 full-year figure at 142761000.0, down 19.92% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 22930000.0, up from 37099000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ALEC reached as high as 9883000.0 in Q2 2022 and fell as low as 52428000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 31929294.12 across 5 years, with a median of 37099000.0 in 2025.
- Across the five-year window, Income from Continuing Operations jumped 117.92% in 2022 and sank 2912.8% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 52428000.0 in 2022, then jumped by 31.73% to 35791000.0 in 2023, then soared by 94.21% to 2074000.0 in 2024, then tumbled by 1688.77% to 37099000.0 in 2025, then soared by 38.19% to 22930000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 22930000.0 in Q1 2026, 37099000.0 in Q4 2025, and 34667000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Alector | 164.78 Mn | -41.74 Mn | - | -22.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.93 Mn |
| Dec 31, 2025 | -37.10 Mn |
| Sep 30, 2025 | -34.67 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -2.07 Mn |
| Sep 30, 2024 | -42.22 Mn |
| Jun 30, 2024 | -38.68 Mn |
| Mar 31, 2024 | -36.08 Mn |
| Dec 31, 2023 | -35.79 Mn |
| Sep 30, 2023 | -44.48 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | -45.86 Mn |
| Dec 31, 2022 | -52.43 Mn |
| Sep 30, 2022 | -46.15 Mn |
| Jun 30, 2022 | 9.88 Mn |
| Mar 31, 2022 | -44.62 Mn |
| Dec 31, 2021 | -47.98 Mn |
| Sep 30, 2021 | 126.60 Mn |
| Jun 30, 2021 | -55.15 Mn |